MGMT methylation: A marker of response to temozolomide in low‐grade gliomas | Zendy

Everhard Sibille | Zendy; Kaloshi Gentian | Zendy; Crinière Emmanuelle | Zendy; BenouaichAmiel Alexandra | Zendy; Lejeune Julie | Zendy; Marie Yannick | Zendy; Sanson Marc | Zendy; Kujas Michèle | Zendy; Mokhtari Karima | Zendy; HoangXuan Khê | Zendy; Delattre JeanYves | Zendy; Thillet Joëlle | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

MGMT methylation: A marker of response to temozolomide in low‐grade gliomas

Author(s) -

Everhard Sibille,

Kaloshi Gentian,

Crinière Emmanuelle,

BenouaichAmiel Alexandra,

Lejeune Julie,

Marie Yannick,

Sanson Marc,

Kujas Michèle,

Mokhtari Karima,

HoangXuan Khê,

Delattre JeanYves,

Thillet Joëlle

Publication year - 2006

Publication title -

annals of neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.764

H-Index - 296

eISSN - 1531-8249

pISSN - 0364-5134

DOI - 10.1002/ana.21044

Subject(s) - temozolomide , methylation , methyltransferase , oncology , glioma , chemotherapy , medicine , o 6 methylguanine dna methyltransferase , glioblastoma , cancer research , biology , gene , genetics

The methylation status of the O6‐methylguanine‐methyltransferase promoter (MGMTP) was evaluated in 68 low‐grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression‐free survival as compared with unmethylated MGMTP tumors ( p < 0.0001). Assessment of MGMTP status could help identifying low‐grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies. Ann Neurol 2006;60:740–743

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research